Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
08 juil. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...